These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 3314025)

  • 1. Induction of tolerance by combined allogeneic and autologous bone marrow transplantation.
    Gratwohl A; Baldomero H; Nissen C; Speck B
    Transplant Proc; 1987 Oct; 19(5):4256-7. PubMed ID: 3314025
    [No Abstract]   [Full Text] [Related]  

  • 2. Protection from graft-versus-host disease in fully allogeneic chimeras by prior administration of T cell-depleted syngeneic bone marrow.
    Sykes M; Chester CH; Sachs DH
    Transplantation; 1988 Aug; 46(2):327-30. PubMed ID: 3043787
    [No Abstract]   [Full Text] [Related]  

  • 3. Monoclonal antibodies to promote marrow engraftment and tissue graft tolerance.
    Cobbold SP; Martin G; Qin S; Waldmann H
    Nature; 1986 Sep 11-17; 323(6084):164-6. PubMed ID: 3528866
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tolerance induction to islet allografts following infusion of perforin deficient bone marrow.
    Selvaggi G; Inverardi L; Levy RB; Mintz DH; Podack ER; Ricordi C
    Transplant Proc; 1995 Dec; 27(6):3193. PubMed ID: 8539907
    [No Abstract]   [Full Text] [Related]  

  • 5. Role of suppressor cells in transplantation tolerance.
    Tutschka PJ; Santos GW; Beschorner W
    Transplant Proc; 1979 Mar; 11(1):882-6. PubMed ID: 156436
    [No Abstract]   [Full Text] [Related]  

  • 6. Adaptive phenomena in bone marrow transplantation.
    Goujet-Zalc C; Ilbery PL
    Exp Hematol; 1973; 1(1):3-10. PubMed ID: 4154047
    [No Abstract]   [Full Text] [Related]  

  • 7. Induction of allogeneic unresponsiveness by supralethal irradiation and bone marrow reconstitution.
    Rapaport FT; Bachvaroff RJ; Akiyama N; Sato T
    Transplant Proc; 1980 Sep; 12(3):473-6. PubMed ID: 7013179
    [No Abstract]   [Full Text] [Related]  

  • 8. Mechanisms of tolerance in marrow transplantation.
    Deeg HJ; Tsoi MS; Storb R
    Transplant Proc; 1984 Aug; 16(4):933-7. PubMed ID: 6235653
    [No Abstract]   [Full Text] [Related]  

  • 9. Effective graft-versus-leukemia effects independent of graft-versus-host disease after T cell-depleted allogeneic bone marrow transplantation in a murine model of B cell leukemia/lymphoma. Role of cell therapy and recombinant IL-2.
    Weiss L; Lubin I; Factorowich I; Lapidot Z; Reich S; Reisner Y; Slavin S
    J Immunol; 1994 Sep; 153(6):2562-7. PubMed ID: 8077666
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction of donor-specific tolerance in sublethally irradiated recipients by gene therapy.
    Forman D; Tian C; Iacomini J
    Mol Ther; 2005 Aug; 12(2):353-9. PubMed ID: 15939670
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mixed autologous allogeneic bone marrow transplantation in rabbits.
    Gratwohl A; Baldomero H; Speck B
    Transplant Proc; 1989 Feb; 21(1 Pt 3):3079-81. PubMed ID: 2523172
    [No Abstract]   [Full Text] [Related]  

  • 12. Blockade of the CD40/CD154 pathway enhances T-cell-depleted allogeneic bone marrow engraftment under nonmyeloablative and irradiation-free conditioning therapy.
    Pan Y; Luo B; Sozen H; Kalscheuer H; Blazar BR; Sutherland DE; Hering BJ; Guo Z
    Transplantation; 2003 Jul; 76(1):216-24. PubMed ID: 12865813
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term observation after simultaneous lung and intra-bone marrow-bone marrow transplantation.
    Kaneda H; Adachi Y; Saito Y; Ikebukuro K; Machida H; Suzuki Y; Minamino K; Zhang Y; Iwasaki M; Nakano K; Koike Y; Wang J; Imamura H; Ikehara S
    J Heart Lung Transplant; 2005 Sep; 24(9):1415-23. PubMed ID: 16143265
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mixed allogeneic chimerism as an approach to transplantation tolerance.
    Sykes M; Sachs DH
    Immunol Today; 1988 Jan; 9(1):23-7. PubMed ID: 3076756
    [No Abstract]   [Full Text] [Related]  

  • 15. A correlation between conditioning and engraftment in recipients of MHC-mismatched T cell-depleted murine bone marrow transplants.
    Soderling CC; Song CW; Blazar BR; Vallera DA
    J Immunol; 1985 Aug; 135(2):941-6. PubMed ID: 3891856
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Composite vascularized skin/bone transplantation models for bone marrow-based tolerance studies.
    Ozmen S; Ulusal BG; Ulusal AE; Izycki D; Siemionow M
    Ann Plast Surg; 2006 Mar; 56(3):295-300. PubMed ID: 16508361
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Suppressor mechanisms active in the control of graft-v-host disease.
    Tutschka PJ
    Transplant Proc; 1987 Dec; 19(6 Suppl 7):69-74. PubMed ID: 2962355
    [No Abstract]   [Full Text] [Related]  

  • 18. Ultraviolet irradiation for the prevention of graft-versus-host disease and graft rejection in bone marrow transplantation.
    Hudson JG; Lawler M; Pamphilon DH
    Bone Marrow Transplant; 1994 Oct; 14(4):511-6. PubMed ID: 7858525
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A nonlethal conditioning approach to achieve durable multilineage mixed chimerism and tolerance across major, minor, and hematopoietic histocompatibility barriers.
    Colson YL; Wren SM; Schuchert MJ; Patrene KD; Johnson PC; Boggs SS; Ildstad ST
    J Immunol; 1995 Nov; 155(9):4179-88. PubMed ID: 7594573
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hematopoietic stem cell graft manipulation as a mechanism of immunotherapy.
    Talmadge JE
    Int Immunopharmacol; 2003 Aug; 3(8):1121-43. PubMed ID: 12860168
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.